ATLANTIS points to maintenance benefit of rucaparib in mUC

Simon Crabb outlines the final results of the rucaparib arm of the ATLANTIS trial of maintenance therapy in patients with metastatic urothelial cancer, and discusses them in light of the recent JAVELIN Bladder 100 and ATLAS trials (4:47).

This independent video interview was supported by an educational grant from Pfizer and Merck Healthcare KGaA, Darmstadt, Germany

Don’t fall behind!

Get the latest headlines – in your specialties of choice – delivered straight to your inbox.

Showcase

FIGARO: Where will finerenone fit into diabetic kidney disease treatment?

MEET THE SENIOR TEAM

Lucy Piper

medwireNews Bureau Chief

Related Showcases

view all

Neurology

Unrestricted oral feedings reported by caregivers and affected persons across severity of…

Conference Coverage & Reporting

Neurology

Feasibility of assisted 6-minute cycle test shown in non-ambulatory SMA patients

Conference Coverage & Reporting

Neurology

Nusinersen treatment may improve aerobic capacity in adult SMA patients

Conference Coverage & Reporting

Neurology

Treatment linked to continued stabilization of motor function in adults with SMA

Conference Coverage & Reporting

Neurology

Study identifies miRNAs upregulated in SMA

Conference Coverage & Reporting

Neurology

EAN 2020 | Teriflunomide shows benefits in children with relapsing forms of…

Conference Coverage & Reporting

Building relationships through trusted content for healthcare professionals

A global leader in medical content